Patients affected by early-stage breast cancer were enrolled in this phase II trial. Patients had to be 60 years old and treated with breast conservative surgery for early stage (pT1-T2 pN0-N1a) invasive ductal carcinoma.
77 patients were enrolled. Median follow-up was 18 months. The proposed schedule was well tolerated. One patient reported Grade 3 pain at the site of irradiation. Four (5 % ) patients experience Grade 2 erythema. Late Grade 2 and 1 fibrosis was observed in 3 (4 % ) and 14 (18 % ) patients, respectively. Cosmesis was judged ¡°good/excellent¡± and ¡°poor¡± in 75 (97 % ) and in 2 (3 % ) patients, respectively.
40?Gy in 10 daily fractions, 4?Gy/fraction, is a well tolerated regimen to deliver PBI.